| Execution period | two years |
|---|
BSE filing, NSE: ROSSARI. Summary written from the filing by ALFA Finder's alert engine.
Rossari Biotech Ltd: key numbers
- Share price
- ₹409.45
- Market cap
- ₹2,268 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 14.8×Sector 33.6×
- Promoter holding
- 68.14%+0.00% QoQ
- FII holding
- 1.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Earnings Call Transcript: Key Takeaways
Rossari Biotech achieved record quarterly revenue and EBITDA despite volatile raw material costs and logistical headwinds.
- Call
- Guides 15% growth
Rossari Biotech Results Update
Rossari Biotech reported Q2 FY27 revenue of Rs. 697.6 crore, up 19% YoY. The company also announced plans for a new manufacturing facility in Saudi Arabia.
Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech reported record quarterly revenue of Rs. 697.6 Cr (up 19% YoY) and EBITDA of Rs. 87 Cr (up 21% YoY). Performance driven by volume and product mix.
Rossari Biotech Q2 FY27 Results: Net Profit ₹38.9 Cr, Up 5.4% YoY
Rossari Biotech Ltd reported revenue from operations of ₹697.6 Cr (+19.0% YoY) and net profit of ₹38.9 Cr (+5.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹38.9 Cr · +5.4% YoY
Rossari Biotech Other Announcement
Rossari Biotech submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing includes minor reporting adjustments for two promoter group members.
Rossari Biotech Board Meeting Date
Rossari Biotech will hold a board meeting on October 17, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.
Other capacity expansion announcements
All →Global Health Capacity Expansion: ₹997 Cr Investment
Medanta plans a 500-bed Ghaziabad hospital over 3-4 years. Project cost is Rs 997 Crore, funded by internal accruals and debt.
- Value
- ₹997.0 Cr
- Execution
- 3-4 years, phased
- hospital beds
- 500.0 beds
Gujarat Inject (Kerala) Capacity Expansion
Gujarat Inject Kerala Ltd leased two Ahmedabad industrial premises for factory and R&D use. The five-year deals include 5% escalation and a two-year lock-in.
- Execution
- 5 years (2-year lessee lock-in)
Aelea Commodities Capacity Expansion: ₹114 Cr Investment
Aelea's board approved ₹114 crore to add 90 MT manufacturing capacity and build a staff housing colony in Surat. Completion expected within 30 months from February 2027.
- Value
- ₹114.0 Cr
- Execution
- 30 months from February 2027
- manufacturing capacity addition
- 90.0 MT
Kaynes Technology India Capacity Expansion
Kaynes Technology has incorporated a wholly owned subsidiary, Kaynes Arabia Electronics Company, in Saudi Arabia to manufacture electronic products for GCC markets. The company holds 100% ownership and the authorised share capital is SAR 100,000.
Vaibhav Vyapaar Capacity Expansion
Vaibhav Vyapaar opened a new business office in Bangalore, commencing operations on 02 November 2026. The approximately 5,500 sq ft office supports operational expansion.
- office area
- 5500.0 sq ft
Borana Weaves Capacity Expansion: ₹49.92 Cr Investment
Borana Weaves plans 384 new looms, adding 110.60 million metres of yearly capacity. The Rs 49.92 Crore investment will be phased through March 2027.
- Value
- ₹49.92 Cr
- Execution
- Phase 1 by December 2026; Phase 2 by March 2027
- annual greige fabric production capacity
- 110.6 million metres per year